Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Debt to Equity (2017 - 2025)

Ani Pharmaceuticals' Debt to Equity history spans 11 years, with the latest figure at $0.54 for Q4 2025.

  • For Q4 2025, Debt to Equity fell 31.51% year-over-year to $0.54; the TTM value through Dec 2025 reached $0.54, down 31.51%, while the annual FY2025 figure was $0.54, 31.51% down from the prior year.
  • Debt to Equity for Q4 2025 was $0.54 at Ani Pharmaceuticals, down from $0.59 in the prior quarter.
  • Across five years, Debt to Equity topped out at $105.88 in Q1 2022 and bottomed at -$15.23 in Q1 2024.
  • The 5-year median for Debt to Equity is $0.58 (2023), against an average of $11.9.
  • The largest annual shift saw Debt to Equity skyrocketed 11659.6% in 2022 before it crashed 864.34% in 2025.
  • A 5-year view of Debt to Equity shows it stood at $0.74 in 2021, then tumbled by 496.3% to -$2.94 in 2022, then soared by 1198.41% to $32.25 in 2023, then crashed by 97.56% to $0.79 in 2024, then tumbled by 31.51% to $0.54 in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Debt to Equity are $0.54 (Q4 2025), $0.59 (Q3 2025), and -$4.09 (Q2 2025).